Eumelanotic cell line derived from a lymph node melanoma metastasis that is sensitive to tyrosine kinase inhibitors, Dasatinib and Sunitinib.
| Inventor | Institute |
|---|---|
| Ghanem Elias, Ahmad Najem | Universite libre de Bruxelles |
| SKU: | 161602 |
|---|---|
| Product description: | Eumelanotic cell line derived from a lymph node metastasis of a female with nodular melanoma. This line displays a proliferative, melanocytic-like phenotype and is sensitive to tyrosine kinase inhibitors, Dasatinib and Sunitinib. |
| Gender: | Female |
| CRISPR: | No |
| Parental cell line: | Ham’s F10 melanoma culture medium (HMCM) |
| Model description: | This cell line displays a Proliferative/ Melanocyte-like phenotype |
| Disease: | Cancer |
| Cat. #: | 161602 |
|---|---|
| Cancer types: | Skin cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Lymphatic |
| Gender: | Female |
| Model: | C-KIT: D820Y |
| Growth properties: | Adherent |
| Cancer Types In Detail: | Melanoma |
| Primary citation: | Eves et al. 2003. Br J Cancer 89. PMID: 14612916 |
| Initial handling information: | The frozen culture should be stored in liquid nitrogen upon arrival or thaw the vial and initiate the culture as soon as possible upon receipt |
|---|---|
| Format: | Frozen |
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry Ice |
| Growth medium: | Ham’s F10 supplemented with 10% of foetal calf serum (FCS), with L-glutamine (1mM), penicillin (100 IU/ml), and streptomycin (100 µg/ml). |
| Subculture routine: | Split sub-confluent cultures (70-80%) 1:3 to 1:8, using 0.05-0.25% trypsin in 0.02% EDTA, 5% CO2, 37°C. |
| Temperature: | 37° C |
| Atmosphere: | 5% CO2 |
| Biosafety level: | 2 |
| References: |
Sabbah et al. 2021. Mol Cancer Res. 19(7):1221-1233. PMID: 33741716 Krayem et al. 2014. Eur J Cancer. 50(7):1310-20. PMID: 24559688 Krayem et al. 2018. Oncotarget. 9(61):31888-31903. PMID: 30159130 Soumoy et al. 2020. Cancers (Basel). 12(5):1323. PMID: 32455924 Porcelli et al. 2015. J Transl Med. 13:26. PMID: 25623468 Wouterset al. 2020. Nat Cell Biol. 22(8):986-998. PMID: 32753671 Verfaillie et al. 2015. Nat Commun 6, 6683. PMID: 25865119 Aftimos et al. 2013. Int J Oncol. 43(3):919-26. PMID: 23835698 Zannat et al. 2013. J Biol Regul Homeost Agents. 27(1):131-41. PMID: 23489693 Mauduit et al. 2021. eLife 10:e71735. PMID: 34874265 Huang et al. 2021. J Clin Invest. 131(8):e140752. PMID: 33690225 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.